CA
NZ
UK
AU
IND
US
…
Blue Water Biotech, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Vaccines, Inc. and changed its name to Blue Water Biotech, Inc. in April 2023. Blue Water Biotech, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -13.42M | -3.42M | -1.60M | -0.82M |
| Net income | -13.29M | -3.42M | -1.58M | -0.76M |
| Selling general administrative | 9.35M | 2.09M | 1.10M | 0.82M |
| Reconciled depreciation | 0.01M | 0.00M | 0.00M | 0.00M |
| Ebit | -13.48M | -3.42M | -1.62M | -0.88M |
| Ebitda | -13.54M | -3.41M | -1.62M | -0.88M |
| Depreciation and amortization | -0.06M | 0.00M | 0.00M | 0.00M |
| Operating income | -13.48M | -3.42M | -1.62M | -0.88M |
| Other operating expenses | 13.48M | 3.42M | 1.62M | 0.88M |
| Interest expense | 0.06M | 0.00M | 0.02M | 0.06M |
| Interest income | - | 0.00M | 0.02M | 0.06M |
| Net interest income | - | 0.00M | 0.02M | 0.06M |
| Income tax expense | -0.13M | - | -0.02M | -0.06M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 13.48M | 3.42M | 1.62M | 0.88M |
| Total other income expense net | 0.06M | - | 0.02M | 0.06M |
| Net income from continuing ops | -13.42M | -3.42M | -1.60M | -0.82M |
| Net income applicable to common shares | -13.52M | -4.04M | -2.16M | -1.10M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 26.31M | 3.08M | 4.81M | 6.08M |
| Other current assets | 0.47M | 1.14M | 0.28M | 0.00M |
| Total liab | 3.92M | 1.64M | 0.08M | 0.08M |
| Total stockholder equity | 22.39M | 1.45M | 4.73M | 6.00M |
| Other current liab | 2.42M | 1.06M | - | 0.06M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -19.38M | -5.96M | -2.54M | -0.94M |
| Other liab | - | - | 0.01M | 0.01M |
| Other assets | 0.04M | - | 0.20M | 0.01M |
| Cash | 25.75M | 1.93M | 4.31M | 6.05M |
| Total current liabilities | 3.92M | 1.64M | 0.07M | 0.08M |
| Net debt | -25.75M | -1.93M | -4.31M | -6.05M |
| Other stockholder equity | 41.76M | 7.40M | 7.27M | 6.94M |
| Property plant equipment | 0.01M | 0.01M | 0.02M | 0.01M |
| Total current assets | 26.26M | 3.07M | 4.60M | 6.06M |
| Net tangible assets | 22.39M | 1.45M | 4.73M | 6.00M |
| Net receivables | 0.04M | 0.15M | 0.01M | 0.01M |
| Inventory | - | -0.15M | - | - |
| Accounts payable | 1.50M | 0.58M | 0.07M | 0.02M |
| Non currrent assets other | 0.04M | - | 0.20M | 0.01M |
| Non current assets total | 0.05M | 0.01M | 0.22M | 0.02M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -0.01M | -0.00M | -0.01M | -0.00M |
| Change to liabilities | 1.09M | 0.34M | 0.05M | 0.02M |
| Total cashflows from investing activities | -0.01M | -0.00M | -0.01M | -0.00M |
| Net borrowings | - | - | - | -0.05M |
| Total cash from financing activities | 32.53M | -0.33M | -0.33M | 6.88M |
| Change to operating activities | 1.47M | 0.99M | -0.48M | -0.02M |
| Net income | -13.42M | -3.42M | -1.60M | -0.82M |
| Change in cash | 23.82M | -2.38M | -1.74M | 6.05M |
| Begin period cash flow | 1.93M | 4.31M | 6.05M | 0.00M |
| End period cash flow | 25.75M | 1.93M | 4.31M | 6.05M |
| Total cash from operating activities | -8.70M | -2.04M | -1.73M | -0.83M |
| Issuance of capital stock | 34.87M | - | 0.00M | 6.93M |
| Depreciation | 0.01M | 0.00M | 0.00M | 0.00M |
| Change to account receivables | -0.02M | -0.11M | -0.04M | -0.01M |
| Sale purchase of stock | -0.57M | - | - | - |
| Other cashflows from financing activities | -1.77M | -0.33M | -0.01M | 6.93M |
| Change to netincome | 2.18M | 0.15M | 0.33M | 0.00M |
| Capital expenditures | 0.01M | 0.00M | 0.01M | 0.00M |
| Change in working capital | 2.54M | 1.21M | -0.47M | -0.01M |
| Stock based compensation | 1.97M | 0.13M | 0.33M | 0.00M |
| Other non cash items | 0.20M | 0.02M | - | - |
| Free cash flow | -8.71M | -2.05M | -1.74M | -0.83M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
0.70 1.76% |
40.70 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.79 0.50% |
556.10 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
39.36 4.24% |
967.25 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Blue Water Biotech, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Vaccines, Inc. and changed its name to Blue Water Biotech, Inc. in April 2023. Blue Water Biotech, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
201 East Fifth Street, Cincinnati, OH, United States, 45202
513 620 4101
12
| Name | Title | Year Born |
|---|---|---|
| Mr. Joseph Hernandez M.S., MBA | CEO, Pres & Exec. Chairman | 1973 |
| Ms. Erin Henderson | Chief Bus. Officer & Corp. Sec. | 1975 |
| Mr. Jon M. Garfield | Chief Financial Officer | 1964 |
| Dr. Brian Price Ph.D. | Head of Technology Strategy | NA |
| Dr. Ronald R. Cobb Ph.D. | Head of Science & Discovery | NA |
| Mr. Andrew D. Skibo Ph.D. | Global Head of Biologics Operations | NA |
| Mr. Theodore Scott Yoho | Head of Bus. Devel. | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.40%
Communication Services
+0.50%
Consumer Cyclical
+1.37%
Consumer Defensive
+0.86%
Energy
-2.31%
Financial Services
+0.99%
Financials
+0.52%
Healthcare
-0.64%
Industrials
+0.63%
Real Estate
+0.65%
Technology
-0.08%
Utilities
+0.01%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...